Is MK-677 with ipamorelin legal in the United Kingdom?

Not one vial but one protocol: a daily oral secretagogue alongside an injected one. Both act at the same receptor, so this is a single mechanism delivered twice. MK-677 is the only component in the growth hormone section of this database with a two-year randomised trial, and that trial showed fat-free mass rose 1.1 kg against a 0.5 kg fall on placebo, with no significant strength or function benefit.

People run these together because one is convenient and slow and the other is injected and fast, and the combination feels like covering both. Pharmacologically it is one receptor, hit twice.

Mechanism: Both components are agonists at the growth hormone secretagogue receptor. MK-677 is orally bioavailable with a long enough duration to sustain raised growth hormone and IGF-1 across the day; ipamorelin is injected and short acting.

Regulatory history: Not approved. MK-677 completed clinical development without an approval and is sold as a research chemical; ipamorelin has never been approved.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for MK-677 with ipamorelin at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.